Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
Conditions
Keywords
head and neck squamous cell carcinoma, Cetuximab, Zimberelimab, neoadjuvant therapy
Brief summary
This study is a single arm phase ll trial including 52 patients with T2N2-3M0#T3-4N0-3M0 (III-V) head and neck squamous cell carcinoma(HNSCC) eligible forresection, who receive Cetuximab+ Zimberelimab combined with cisplatin and Nab.paclitaxel.This proposed study will evaluate the efficacy and safety of preoperative administration of Cetuximab+ Zimberelimab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma(HNSCC) who are about to undergo surgery.
Detailed description
In this study, eligible subject will be enrolled into study arm to accept study treatment objective response rate will be the primary outcome measures.
Interventions
DRUGCetuximab
Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
DRUGZimberelimab
Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
DRUGDocetaxel
Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
DRUGCisplatin
Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
Sponsors
Xuekui Liu
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Newly diagnosed primary head and neck squamous cell carcinoma confirmed by histology and/or cytology (excluding diagnostic therapy). 2. Clinical stage:T2N2-3M0,T3-4N0-3M0 (AJCC 8th editionstaging). 3. Age: 18 to 70 years. 4. PS score (see Appendix Table 1; performance status score of 0 or 1). 5. Patients evaluated by a head and neck oncologist as resectable with no distant metastases. 6. Patients with at least one measurable lesion according to RECIST version 1.1 criteria. 7. Patients' toxicities assessed according to CTCAE version 4.03 criteria. 8. Patients with normal organ function (heart,brain, lungs, kidneys) and suitable for surgery: 1. Hematology: White blood cells ≥ 3500/μL,neutrophils ≥1,800/pL, hemoglobin ≥ 9 g/dL, platelets ≥100,000/μL; 2. Liver function: Bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with known Gilbert's disease and serum bilirubin levels ≤ 3 times ULN can be included), AST and ALT ≤3 times ULN, alkaline phosphatase ≤ 3 times ULN; albumin ≥ 3 g/dL; c.Renal function: Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60 mL/min according to Cockcroft-Gault formula. 9. Patients have signed an informed consent form, are willing and able to comply with the study's visit, treatment plan, laboratory tests, and other study procedures.
Exclusion criteria
1. History of severe hypersensitivity reactions to components of other monoclonal antibodies, CTLA4, or PD-1 antibodies. 2. Patients with known or suspected autoimmune diseases, including dementia and epileptic seizures. 3. Recurrence, distant metastasis, or the inability to undergo surgery as assessed by a head and neck physician. 4. Abnormal coagulation function:(PT \> 16s,APTT\>53s,TT\> 21s, Fib \< 1.5g/L), bleeding tendency, or currently on anticoagulant or thrombolytic therapy. 5. Severe heart disease, pulmonary dysfunction, patients with heart or lung function below Grade 3 (including Grade 3). 6. Laboratory values not meeting relevant criteria within 7 days prior to enrollment. 7. Previous use of anti-PD-1 antibodies, anti-PD-L1 antibodies,anti-PD-L2 antibodies, or anti-CTLA-4 antibodies (or any other antibodies targeting T cell co-stimulation or checkpoint pathways). 8. Pre-existing conditions requiring long-term use of immunosuppressive drugs or a need for systemic or local use of corticosteroids at immunosuppressive doses prior to enrollment. 9. HIV-positive individuals;HBsAg-positive individuals with positive HBV DNA copy number (quantitative test≥1000 cps/ml); positive chronic hepatitis C blood screening(HCV antibody positive). 10. Traditional herbal medicine used for anti-tumor purposes within 4 weeks before randomization. 11. Women of childbearing potential with a positive pregnancy test and breastfeeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 9 weeks | overall response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MPR | 9 weeks | Major Pathological Response |
| DCR | 2 years | Disease Control Rate |
| PCR | 9 weeks | pathological Complete Response |
| OS | 5 years | Overall survival |
| Adverse Events Graded By Ctcae V5.0 | 90 days after the first dose of study treatment | Percentage of adverse events that are possibly, probably related to study treatment per Criteria for Adverse Events version 5(CTCAE v5.0) |
| PFS | 2 years | Progression-Free survival |
Countries
China
Contacts
Primary ContactXuekui Liu
Outcome results
None listed